| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology [H. T., H-C. C., C. A. B., K. B., P. C. L., B. A. R., A. C., I. B., M. A. M., S. A. K., J. J. M., S. C. R., J. B.], Division of Hematology-Oncology, Department of Medicine [F. J. C., B. L. W.], and Division of Anatomic Pathology, Department of Pathology and Laboratory Medicine [V. A. L.], University of Pennsylvania Medical Center and University of Pennsylvania Comprehensive Cancer Center [B. L. W., V. A. L., I. B., M. A. M., S. A. K., J. J. M., S. C. R., J. B.], Philadelphia, Pennsylvania 19104, and Department of Pathology, Jikei University School of Medicine, Tokyo 105, Japan [M. F.]
Inherited mutations in the recently discovered BRCA2 gene are believed to be responsible for a significant fraction of early-onset hereditary breast cancers. Unlike BRCA1, however, which confers a high risk to both breast and ovarian cancer, the incidence of ovarian cancer appears to be much lower in BRCA2-linked families, causing uncertainty as to the relevance of BRCA2 to hereditary ovarian cancer. Numerous allelotype studies indicate that allelic deletions including the BRCA2 locus on chromosome 13q are common in ovarian cancers in general, suggesting that somatic mutations of this gene may be involved in sporadic ovarian tumorigenesis. The purpose of this study was to test the hypothesis that germline or somatic mutations of BRCA2 are associated with hereditary and/or sporadic ovarian cancers, respectively. The entire 10.2-kb coding region of BRCA2 was screened for mutations in 130 consecutive ovarian tumors, the only selection criterion being a pathological diagnosis of epithelial ovarian carcinoma. Loss of heterozygosity at markers flanking BRCA2 was observed in 56% of the tumors. Four germline mutations and two somatic mutations were identified; two of the germline mutations are recurrent, having been previously described. Remarkably, the patients with germline mutations were late-onset cases with no medical or family histories suggestive of hereditary cancer. These data suggest that mutations of BRCA2 are rare in sporadic ovarian cancers, and that the proportion of ovarian cancers resulting from hereditary predisposition may be higher than previously suspected based on estimates derived from studies of highly penetrant genetic loci.
1 To whom requests for reprints should be addressed, at Department of Obstetrics and Gynecology, University of Pennsylvania Medical Center, 415 Curie Boulevard, 778 Clinical Research Building, Philadelphia, PA 19104.
Received 4/26/96. Accepted 5/ 1/96.
This article has been cited by other articles:
|
|
 |
|
  H. A. Risch, J. R. McLaughlin, D. E. C. Cole, B. Rosen, L. Bradley, I. Fan, J. Tang, S. Li, S. Zhang, P. A. Shaw, et al. Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin-Cohort Study in Ontario, Canada J Natl Cancer Inst, December 6, 2006; 98(23): 1694 - 1706. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Payne and C. J. Kemp Tumor suppressor genetics Carcinogenesis, December 1, 2005; 26(12): 2031 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Levine, P. A. Argenta, C. J. Yee, D. S. Marshall, N. Olvera, F. Bogomolniy, J. A. Rahaman, M. E. Robson, K. Offit, R. R. Barakat, et al. Fallopian Tube and Primary Peritoneal Carcinomas Associated With BRCA Mutations J. Clin. Oncol., November 15, 2003; 21(22): 4222 - 4227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Hilton, J. P. Geisler, J. A. Rathe, M. A. Hattermann-Zogg, B. DeYoung, and R. E. Buller Inactivation of BRCA1 and BRCA2 in Ovarian Cancer J Natl Cancer Inst, September 18, 2002; 94(18): 1396 - 1406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. Martin and B. L. Weber Genetic and Hormonal Risk Factors in Breast Cancer J Natl Cancer Inst, July 19, 2000; 92(14): 1126 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Sinclair, R. Berry, D. Schaid, S. N. Thibodeau, and F. J. Couch BRCA1 and BRCA2 Have a Limited Role in Familial Prostate Cancer Cancer Res., March 1, 2000; 60(5): 1371 - 1375. [Abstract] [Full Text]
|
|
|
|
 |
|
 J.E. V. Watson, H. Gabra, K. J. Taylor, G. J. Rabiasz, H. Morrison, P. Perry, J. F. Smyth, and D. J. Porteous Identification and Characterization of a Homozygous Deletion Found in Ovarian Ascites by Representational Difference Analysis Genome Res., March 1, 1999; 9(3): 226 - 233. [Abstract] [Full Text]
|
|
|
|
|
|
R. E. Buller, A. K. Sood, T. Lallas, T. Buekers, and J. S. Skilling Association Between Nonrandom X-Chromosome Inactivation and BRCA1 Mutation in Germline DNA of Patients With Ovarian Cancer J Natl Cancer Inst, February 17, 1999; 91(4): 339 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Y. Marmorstein, T. Ouchi, and S. A. Aaronson The BRCA2 gene product functionally interacts with p53 and RAD51 PNAS, November 10, 1998; 95(23): 13869 - 13874. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Piver Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate Oncologist, October 1, 1996; 1(5): 326 - 330. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
